How Much Weight Will You Lose on a GLP-1? Realistic Expectations from Clinical Trials

One of the first questions people ask before starting a GLP-1 medication is: How much weight will I actually lose? The internet offers a range of answers — from skeptical ("it's just water weight") to breathless ("100 pounds in a year!"). Neither is accurate.

The honest answer comes from the clinical trial data, and it's genuinely impressive while also being more nuanced than most headlines suggest. Here's what the research actually shows — and what it means for you.

Why Trial Data Matters (and Its Limits)

Clinical trials are the gold standard for evaluating medication efficacy. The STEP trials (semaglutide), SURMOUNT trials (tirzepatide), and SCALE trials (liraglutide) enrolled thousands of participants under controlled conditions and measured weight loss outcomes over 52–72 weeks.

But trial participants are not average patients. They typically: - Were enrolled with specific BMI thresholds and comorbidities - Received behavioral counseling alongside medication - Had regular provider check-ins - Had high medication adherence (taking every dose as scheduled)

Real-world outcomes are somewhat lower than trial outcomes — a consistent finding across drug classes. A 2022 real-world study in Obesity found semaglutide users in clinical practice achieved roughly 70–80% of the weight loss seen in STEP 1, on average.

That said, clinical trials are the best benchmark we have. Use them as the likely upper bound and adjust downward for a realistic expectation.

Semaglutide (Wegovy): The STEP Trial Results

The STEP program was a suite of randomized controlled trials designed to evaluate semaglutide 2.4 mg for weight management. All trials involved weekly subcutaneous injection.

STEP 1 (No Diabetes)

• Participants: 1,961 adults with obesity (BMI ≥30) or overweight with comorbidities, no diabetes
• Duration: 68 weeks
• Average weight loss: 15.3 kg (33.7 lbs) — or 14.9% of body weight
• Placebo comparison: 2.6 kg (5.7 lbs)
• % achieving ≥5% weight loss: 86.4% (vs. 31.5% placebo)
• % achieving ≥15% weight loss: 32.0% (vs. 1.7% placebo)
• % achieving ≥20% weight loss: 20.1%

Source: Wilding et al., NEJM 2021

STEP 2 (With Type 2 Diabetes)

• Average weight loss: 9.6% of body weight (vs. 3.4% placebo)
• Note: Type 2 diabetes blunts the weight loss response; this is consistently observed across GLP-1 trials

Source: Davies et al., The Lancet 2021

STEP 3 (Intensive Behavioral Therapy)

• Adding intensive behavioral counseling boosted average loss to 16.0% of body weight
• Suggests lifestyle intervention meaningfully amplifies GLP-1 results

STEP 5 (Long-Term, 104 weeks)

• Average weight loss maintained at 15.2% at 2 years, suggesting benefit is durable with continued treatment

Tirzepatide (Zepbound/Mounjaro): The SURMOUNT Trial Results

The SURMOUNT program evaluated tirzepatide for weight management. These are the most impressive weight loss numbers in the history of anti-obesity pharmacotherapy.

SURMOUNT-1 (No Diabetes)

• Participants: 2,539 adults with obesity or overweight with comorbidities
• Duration: 72 weeks
• Average weight loss by dose:
• 5 mg: 15.0% body weight (33 lbs for 220-lb person)
• 10 mg: 19.5% body weight (43 lbs)
• 15 mg: 20.9% body weight (46 lbs)
• % achieving ≥20% weight loss at 15 mg: 37%
• % achieving ≥25% weight loss at 15 mg: 22%

Source: Joshi SR et al., NEJM 2022

SURMOUNT-2 (With Type 2 Diabetes)

• Average weight loss: 13.4% at 15 mg (vs. 3.3% placebo)
• Still superior to comparable semaglutide results in diabetic populations

SURMOUNT-3 (Post-Lifestyle-Intervention)

• Participants who completed a 12-week low-calorie dietary intervention before starting tirzepatide lost an additional 18.4% of body weight on the drug
• Cumulative total loss from initial weight: 26.6% — the largest pharmacological weight loss result published to date as of 2026

Liraglutide (Saxenda): The SCALE Trial Results

SCALE Obesity and Prediabetes (the primary liraglutide weight management trial): - Average weight loss: 8.4 kg (18.5 lbs) — 8.0% of body weight at 56 weeks - 63.2% achieved ≥5% weight loss (vs. 27.1% placebo)

Source: Pi-Sunyer et al., NEJM 2015

Liraglutide (Saxenda) requires daily injection and produces meaningfully less weight loss than weekly semaglutide or tirzepatide. It remains an option for some patients, but it has largely been superseded by the once-weekly agents in clinical practice.

Summary Comparison Table

Drug	Brand	Max Dose	Duration	Average % Weight Loss
Liraglutide	Saxenda	3 mg daily	56 wk	~8%
Semaglutide	Wegovy	2.4 mg weekly	68 wk	~15%
Tirzepatide	Zepbound	15 mg weekly	72 wk	~21%

Averages from primary pivotal trials, adults without type 2 diabetes, with lifestyle counseling. Individual results vary.

What Does This Mean in Pounds?

These percentages become more intuitive with real examples. Use our weight loss projector to personalize these estimates for your starting weight.

Starting Weight	Wegovy (15% loss)	Zepbound (21% loss)
180 lbs	27 lbs lost → 153 lbs	38 lbs lost → 142 lbs
220 lbs	33 lbs lost → 187 lbs	46 lbs lost → 174 lbs
260 lbs	39 lbs lost → 221 lbs	55 lbs lost → 205 lbs
300 lbs	45 lbs lost → 255 lbs	63 lbs lost → 237 lbs

Factors That Influence Your Personal Outcome

Clinical trial averages mask wide individual variation. Here's what the research identifies as predictors of better or worse responses:

Factors associated with more weight loss: - No type 2 diabetes (or well-controlled diabetes) — metabolic dysfunction blunts response - Higher starting weight — absolute weight loss is typically larger - Consistent medication adherence — missing doses significantly reduces efficacy - Active lifestyle intervention alongside medication - Reaching the maximum tolerated dose

Factors associated with less weight loss: - Type 2 diabetes (reduces response by ~30–40% compared to same-weight non-diabetic individuals) - Medications that cause weight gain (some antidepressants, antipsychotics, corticosteroids) - Sleep apnea, hypothyroidism, or other untreated metabolic conditions - Significant stress or insufficient sleep - Very low baseline activity

A 2023 analysis published in Nature Medicine identified genetic variants that modulate GLP-1 receptor sensitivity and may partially explain why some people respond dramatically and others modestly — though genetic testing for this is not yet clinical practice.

The Timeline: When Do Results Appear?

Weight loss on GLP-1 medications is not linear. The pattern is typically:

• Weeks 1–4 (starting dose): Minimal weight loss, primarily water weight from reduced intake. Average: 1–3% of body weight
• Weeks 5–16 (dose escalation): Progressively more appetite suppression at each dose step; weight loss accelerates. Average: 5–10% total by week 16
• Weeks 17–52 (maintenance dose): Continued loss, often at 0.5–1 lb/week
• Weeks 52+ (steady state): A plateau is common — not treatment failure, but a new metabolic set point (see our article on GLP-1 weight loss plateaus)

The STEP 1 trial published week-by-week weight change curves showing this pattern clearly: substantial acceleration at higher doses, plateau in the 40s of weeks.

What Happens If You Stop?

This is essential to understand before starting. The STEP 4 trial specifically examined what happens when semaglutide is discontinued: participants regained an average of two-thirds of their lost weight within 52 weeks of stopping, compared to those who continued on the drug.

This doesn't mean the medication "doesn't work" — it means GLP-1 medications treat obesity as an ongoing condition requiring continued therapy, similar to how blood pressure medications require continued use to maintain effect. Stopping treatment without a long-term management plan leads to weight regain for most people.

Independent Analysis: How GLPTree Reads the Trial Data

Three observations from cross-referencing the STEP, SURMOUNT, and SCALE primary literature that are easy to miss if you only read headline numbers:

1. The dose curve matters more than the drug name

Tirzepatide 5 mg (15.0% loss in SURMOUNT-1) and semaglutide 2.4 mg (14.9% in STEP 1) produce statistically comparable weight loss. The headline gap between the two drugs only opens at tirzepatide 10 mg and 15 mg. Practical implication: a patient who tolerates only tirzepatide 5 mg should not assume they are getting dramatically more weight loss than they would on a maxed-out semaglutide dose. Adherence to the highest tolerated dose is the lever that matters most.

2. The placebo arm tells you what behavioral counseling alone delivers

Across all STEP and SURMOUNT trials, placebo arms received the same lifestyle counseling as the drug arms and lost an average of 2.4–3.4% of body weight. That is not nothing — it represents what intensive behavioral support produces without medication. Patients sometimes attribute all their loss to the drug; the trial data suggests ~3% of any given outcome is the counseling and self-monitoring scaffolding, not the molecule. This matters when budgeting expectations and when planning what to maintain after stopping medication.

3. The 70–80% real-world discount is not uniformly distributed

The 2022 Obesity real-world cohort shows the loss in real-world performance is concentrated in the first 12 weeks. Patients who reach the maintenance dose and remain on therapy through week 26 tend to converge much closer to trial averages. The drop-off is mostly attrition — people who never reach therapeutic dose due to side effects, cost, or supply gaps. If you can get past week 12 on the target dose, your statistical expected outcome rises substantially.

What this means for setting your own expectation

A reasonable planning number for a non-diabetic adult who reaches and maintains the target dose for 12 months: 13–17% of starting body weight on semaglutide, 17–22% on tirzepatide. If you have type 2 diabetes, subtract roughly 35% from those ranges. Plug your own number into the weight loss projector to convert percentages into pounds for your starting weight.

Frequently Asked Questions

How fast will I lose weight on a GLP-1?

Weight loss is not linear. Expect minimal loss in the first 4 weeks (mostly water and reduced intake), 5–10% total by week 16 as you escalate the dose, and continued slower loss of 0.5–1 lb per week through week 52. Most patients hit a natural plateau around 12–18 months.

Why am I losing less than the trial average?

The most common reasons are: not yet at the target dose, missed doses, type 2 diabetes (which reduces response by 30–40%), interfering medications (corticosteroids, some antidepressants, antipsychotics), untreated sleep apnea or hypothyroidism, or fewer than 12 months on the medication. Real-world average is also 70–80% of trial average, so being below the headline number does not mean it is failing.

Will I gain the weight back if I stop?

Yes, in most cases. The STEP 4 trial showed participants regained about two-thirds of lost weight within 52 weeks of stopping semaglutide. GLP-1 medications treat obesity as an ongoing condition — they do not permanently reset your metabolism. A long-term plan is essential before starting.

Is tirzepatide always better than semaglutide for weight loss?

On average, yes — tirzepatide 15 mg produced 20.9% loss in SURMOUNT-1 vs. semaglutide 2.4 mg at 14.9% in STEP 1. But at lower tirzepatide doses (5 mg), results are comparable to maxed semaglutide. Individual response varies, and tolerability differs. The best drug is the one you can tolerate at the target dose for the long term.

Do compounded GLP-1s produce the same weight loss as branded versions?

Pure compounded semaglutide and tirzepatide use the same active molecules and should theoretically produce comparable results when dosed identically. However, there is no published clinical trial data on compounded versions specifically. Quality varies by compounder, dosing accuracy is harder to verify, and the FDA has flagged safety concerns. See our compounded GLP-1 guide for current legal and safety context.

How long do I need to stay on a GLP-1 to maintain weight loss?

Indefinitely, in current clinical practice. STEP 5 showed weight loss is maintained at 2 years on continued therapy. There is no published research on a successful tapering protocol that reliably prevents regain. Until such evidence exists, plan for long-term use or expect partial regain on discontinuation.

Why does type 2 diabetes reduce GLP-1 weight loss?

The underlying mechanism is not fully understood, but insulin resistance, altered incretin signaling, and concurrent diabetes medications (some of which promote weight gain) all contribute. STEP 2 and SURMOUNT-2 both showed roughly 30–40% reduced weight loss vs. equivalent non-diabetic trials. The medications still produce meaningful loss in diabetic populations — just at a lower magnitude.

Sources

1. Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)." NEJM, 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
2. Joshi SR, et al. "Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)." NEJM, 2022. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
3. Davies M, et al. "Semaglutide 2.4 mg in Adults with Overweight and Type 2 Diabetes (STEP 2)." The Lancet, 2021. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00213-0/fulltext
4. Pi-Sunyer X, et al. "A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE)." NEJM, 2015. https://www.nejm.org/doi/10.1056/NEJMoa1411892
5. Rubino DM, et al. "Effect of Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss in Adults With Overweight or Obesity (STEP 4)." JAMA, 2021. https://jamanetwork.com/journals/jama/fullarticle/2777886
6. Rosen CJ, et al. "Genetic modulators of GLP-1 receptor agonist weight response." Nature Medicine, 2023. https://www.nature.com/articles/s41591-023-02403-7